A recent study validated that PF’s reversal of abnormal liver function and hepatic steatosis in db/db mice is linked to the inhibition of the TXNIP/NLRP3 signaling pathway, indicating TXNIP as a possible target of PF (Wang et al., 2022d). Here, TXNIP is linked to fatty liver disease.